NS-863 clinical trials
NS-863 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 2. The sponsor is Ns Pharma Inc. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.
Patient leaflets for NS-863
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
NS-863 in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product named NS-863. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
2025-525115-16-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 2 | Authorised | Ns Pharma Inc | Italy |
|
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)
2025-525114-38-00 · CTIS ↗ · Respiratory Tract Diseases
|
Phase 2 | Authorised | Ns Pharma Inc | France, Germany, Poland + 4 more |
Conditions studied with NS-863
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Ns Pharma Inc | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Questions about NS-863 trials
How many clinical trials are testing NS-863?
2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named NS-863, as of the registry sync on 17 October 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.
Who sponsors NS-863 clinical trials?
The lead sponsor is Ns Pharma Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how NS-863 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NS-863 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, product names, phase, status, sponsor, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NS-863 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 17 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.